Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
We have a wide range of fun and festive designs to choose from. Fund life changing research while spreading joy this Christmas!
This Christmas, your gift can bring us closer to a cure for type 1 diabetes – and every pound you give to our Christmas Appeal will be doubled.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
This event is designed for anyone living with type 1 diabetes who would like to learn more about managing their wellbeing across a variety of contexts.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
Home > News & events > News > JDRF sponsors Daphne Jackson Fellowship
Have you taken a break from your research career and are now looking to return to work? Are you seeking an opportunity to re-establish your skills and make a positive impact in your field?
We are delighted to announce our latest partnership funding opportunity, offered through the Daphne Jackson Trust. The JDRF-sponsored Fellowship is for a researcher with an interest in type 1 diabetes to return to work after a career break and make a difference in their field.
There are around 400,000 people living with type 1 diabetes in the UK and currently there is no cure. Here at JDRF, we’re committed to supporting research to improve the lives of people affected by type 1 diabetes and one day eradicate the condition for good.
Rachel Connor, Director of Research Partnerships at JDRF UK said, “JDRF is very excited to be working with the Daphne Jackson Trust to support people returning to type 1 diabetes research.”
These Fellowships offer three-year part-time funding for individuals wishing to return to research after a career break of two years or more. The Fellowships must be undertaken at a UK university and involve a challenging research project that addresses a question of relevance to type 1 diabetes and its associated complications. Fellows additionally benefit from an individually tailored retraining programme throughout the course of their Fellowship.
Helen Marsh, Trust Manager at the Daphne Jackson Trust said, “We are very excited to be working with JDRF and delighted that they are sponsoring a Daphne Jackson Fellowship, supporting a research returner to get back into their career. JDRF make a real difference to people’s lives with type 1 diabetes, and their research is crucial.”
For more details about the eligibility criteria and the application process, please visit: www.daphnejackson.org. For further information before submitting an application, please contact the Daphne Jackson Trust via email at email@example.com.
The research, which was co-funded by JDRF, reveals that drugs that target the immune system offer very effective and rapid improvements in stabilising blood sugar levels, often within just three months.
The new JDRF-funded clinical trial called SOPHIST will test a drug to help people with type 1 diabetes and heart failure.
Results from a clinical trial called the PROTECT study show that teplizumab can preserve beta cell function in children and adolescents newly diagnosed with type 1 diabetes.
Don’t miss out on the latest research, inspiring stories, tech news, upcoming events, and handy information on living well with type 1. Join us now and receive it all straight to your inbox.
It’s thanks to your dedication that we have funded great progress in type 1 cure, treatment and prevention research. Help us to continue our vital research.